PRECISION BIOSCIENCES INC
For the period ended Jan 12, 2026. Filed Jan 13, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jan 12, 2026 · Filed Jan 13, 2026
DTIL$10.60+7.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · About FUNCTION-DMD Trial:
About FUNCTION-DMD Trial:
The Phase 1/2 FUNCTION-DMD study is expected to enroll ambulatory DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD. Pending IND clearance, the clinical trial is anticipated to begin dosing patients at world class sites starting in late Q1/early-Q2 with initial clinical data from multiple patients expected later in 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.